Faculty, Staff and Student Publications

Publication Date

1-1-2025

Journal

Head & Neck

DOI

10.1002/hed.27887

PMID

39073252

PMCID

PMC11729999

PubMedCentral® Posted Date

1-1-2026

PubMedCentral® Full Text Version

Author MSS

Abstract

Background: Treatment for dural recurrence of olfactory neuroblastoma (ONB) is not standardized. We assess the outcomes of stereotactic body radiotherapy (SBRT) in this population.

Methods: ONB patients with dural recurrences treated between 2013 and 2022 on a prospective registry were included. Tumor control, survival, and patient-reported quality of life were analyzed.

Results: Fourteen patients with 32 dural lesions were evaluated. Time to dural recurrence was 58.3 months. Thirty lesions (94%) were treated with SBRT to a median dose of 27 Gy in three fractions. Two patients (3 of 32 lesions; 9%) developed in-field radiographic progression, five patients (38%) experienced progression in non-contiguous dura. Two-year local control was 85% (95% CI: 51-96%). There were no >grade 3 acute toxicities and 1 case of late grade 3 brain radionecrosis.

Conclusion: In this largest study of SBRT reirradiation for ONB dural recurrence to date, high local control rates with minimal toxicity were attainable.

Keywords

Humans, Radiosurgery, Female, Male, Esthesioneuroblastoma, Olfactory, Prospective Studies, Aged, Middle Aged, Neoplasm Recurrence, Local, Nose Neoplasms, Aged, 80 and over, Nasal Cavity, Cohort Studies, Quality of Life, Dura Mater, Adult, dural recurrence, esthesioneuroblastoma, olfactory neuroblastoma, SBRT, stereotactic radiation

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.